Dataset Information

Solid-State Dispersions of Platinum in the SnO₂ and Fe₂O₃ Nanomaterials.

ABSTRACT: The dispersion of platinum (Pt) on metal oxide supports is important for catalytic and gas sensing applications. In this work, we used mechanochemical dispersion and compatible Fe(II) acetate, Sn(II) acetate and Pt(II) acetylacetonate powders to better disperse Pt in Fe₂O₃ and SnO₂. The dispersion of platinum in SnO₂ is significantly different from the dispersion of Pt over Fe₂O₃. Electron microscopy has shown that the elements Sn, O and Pt are homogeneously dispersed in α-SnO₂ (cassiterite), indicating the formation of a (Pt,Sn)O₂ solid solution. In contrast, platinum is dispersed in α-Fe₂O₃ (hematite) mainly in the form of isolated Pt nanoparticles despite the oxidative conditions during annealing. The size of the dispersed Pt nanoparticles over α-Fe₂O₃ can be controlled by changing the experimental conditions and is set to 2.2, 1.2 and 0.8 nm. The rather different Pt dispersion in α-SnO₂ and α-Fe₂O₃ is due to the fact that Pt⁴⁺ can be stabilized in the α-SnO₂ structure by replacing Sn⁴⁺ with Pt⁴⁺ in the crystal lattice, while the substitution of Fe³⁺ with Pt⁴⁺ is unfavorable and Pt⁴⁺ is mainly expelled from the lattice at the surface of α-Fe₂O₃ to form isolated platinum nanoparticles.

SUBMITTER: Radin E

PROVIDER: S-EPMC8704069 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:The maximum achievable concentration of a drug in solution is dictated by the chemical potential of the solid form. Because an amorphous solid has a higher chemical potential than the corresponding crystal form, in the absence of phase transformations, a higher transient solubility is expected. However, the chemical potential of an amorphous drug can be reduced by mixing with another component. Therefore, upon mixing with a polymer to form an amorphous solid dispersion (ASD), the maximum solution concentration achieved can be potentially altered, in particular if the polymer is poorly soluble in the dissolution medium. Such changes in the chemical potential of the drug may be a critical factor in determining the maximum achievable solution concentration, and could alter the crystallization driving force of the drug. Therefore, the aim of this study was to gain insights into the impact of poorly soluble polymers on the "amorphous solubility" of drugs formulated as amorphous solid dispersions. Lopinavir was selected as a model drug with a low crystallization tendency, enabling determination of the amorphous solubility as a function of ASD composition. Model polymers included cellulose acetate (CA), CA phthalate (CAP), ethylcellulose (EC), Eudragit® RL PO (EUD), hydroxypropylmethylcellulose (HPMC), HPMC acetate succinate (HPMCAS), and HPMC phthalate (HPMCP). The "amorphous solubility" of the drug alone was determined and then the changes in maximum achievable concentration were measured as a function of drug loading. Drug-polymer interactions were characterized using infrared spectroscopy (IR), differential scanning calorimetry (DSC) and moisture sorption analysis. The results showed that the maximum achievable concentration ("amorphous solubility") of lopinavir varied with the extent of drug-polymer interactions, as well as the drug weight fraction in the ASD. This information is of great value when evaluating the maximum achievable concentration of amorphous systems formulated with pH responsive polymers, and should contribute to a broader understanding of drug phase behavior in the context of ASDs.

Dataset Information

Solid-State Dispersions of Platinum in the SnO₂ and Fe₂O₃ Nanomaterials.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Solid-State Dispersions of Platinum in the SnO2 and Fe2O3 Nanomaterials.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Solid-State Dispersions of Platinum in the SnO₂ and Fe₂O₃ Nanomaterials.